TuHURA Biosciences (HURA) News Today $2.70 -0.11 (-3.91%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.72 +0.02 (+0.74%) As of 08/29/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock HURA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period TuHURA Biosciences (NASDAQ:HURA) Stock Rating Lowered by Wall Street ZenAugust 30 at 2:47 AM | americanbankingnews.comTuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment ConferenceAugust 20, 2025 | prnewswire.comTuHURA Biosciences (NASDAQ:HURA) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPSAugust 18, 2025 | marketbeat.comTuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateAugust 14, 2025 | prnewswire.comTuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Rating of "Buy" from BrokeragesAugust 14, 2025 | marketbeat.comTuHURA Biosciences files to sell 4.76M shares of common stock for holdersAugust 12, 2025 | msn.comTuHURA Biosciences, Inc.'s (NASDAQ:HURA) last week's 11% decline must have disappointed retail investors who have a significant stakeAugust 12, 2025 | finance.yahoo.comTuHURA Biosciences (NASDAQ:HURA) Stock Acquired Rep. Laurel M. LeeAugust 12, 2025 | marketbeat.comTuHURA Biosciences (NASDAQ:HURA) Upgraded by Wall Street Zen to "Hold" RatingJuly 19, 2025 | marketbeat.comTuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Rating of "Buy" from BrokeragesJuly 19, 2025 | marketbeat.comTuHURA Biosciences, Inc. Common Stock (HURA) Insider ActivityJuly 14, 2025 | nasdaq.comTuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - Seeking AlphaJuly 3, 2025 | seekingalpha.comTuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - MorningstarJuly 3, 2025 | morningstar.comMHC Wainwright Has Negative Forecast for HURA FY2025 EarningsJuly 2, 2025 | marketbeat.comTuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJuly 1, 2025 | finance.yahoo.comTuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJuly 1, 2025 | prnewswire.comTuHURA Biosciences, Inc.: TuHURA Biosciences Completes Acquisition of KinetaJune 30, 2025 | finanznachrichten.deTuHURA Biosciences Completes Acquisition of KinetaJune 30, 2025 | prnewswire.comTuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals - MorningstarJune 25, 2025 | morningstar.comMTuHURA initiates phase 3 trial for cancer immunotherapy drugJune 25, 2025 | uk.investing.comTuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or ...June 25, 2025 | morningstar.comMBrookline Capital Management Predicts HURA Q2 EarningsJune 25, 2025 | marketbeat.comTuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Recommendation of "Buy" from BrokeragesJune 24, 2025 | marketbeat.comTuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell CarcinomaJune 24, 2025 | prnewswire.comTuHURA Biosciences (NASDAQ:HURA) Upgraded by Brookline Capital Management to "Strong-Buy" RatingJune 24, 2025 | marketbeat.comTuhura Biosciences Surges After-Hours As Investors Bet On Kineta Merger, Cancer Drug PipelineJune 23, 2025 | msn.comTuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related ProposalsJune 23, 2025 | prnewswire.comTuHURA Biosciences announces executive salary increasesJune 14, 2025 | uk.investing.comTuHURA Biosciences Approves Executive Salary IncreasesJune 12, 2025 | tipranks.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of ShareholdersJune 9, 2025 | prnewswire.comTuHURA Biosciences stock rises following FDA hold liftJune 9, 2025 | au.investing.comTuHURA Biosciences to Continue Carcinoma Drug Trials Following Regulatory Hold LiftJune 9, 2025 | marketwatch.comFDA Clears Path for TuHURA Biosciences (HURA) to Advance Phase 3 Trial | HURA Stock NewsJune 9, 2025 | gurufocus.comFDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for ...June 9, 2025 | gurufocus.comFDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for ...June 9, 2025 | gurufocus.comFDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell CarcinomaJune 9, 2025 | prnewswire.comTuHURA Biosciences: Promising Oncology Advancements and Strategic Acquisitions Drive Buy RatingJune 6, 2025 | tipranks.comTuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer ImmunotherapyJune 3, 2025 | prnewswire.comTuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of ...June 2, 2025 | gurufocus.comTuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual MeetingJune 2, 2025 | prnewswire.comTuHURA Biosciences: Encountering Serious Cash Issues And A Long TimelineMay 28, 2025 | seekingalpha.comQ3 EPS Forecast for TuHURA Biosciences Reduced by AnalystMay 24, 2025 | marketbeat.comKineta and TuHURA Biosciences Announce Merger AgreementMay 23, 2025 | tipranks.comEquities Analysts Set Expectations for HURA FY2027 EarningsMay 23, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for HURA FY2025 Earnings?May 21, 2025 | marketbeat.comHURA: First Quarter 2025 ResultsMay 19, 2025 | finance.yahoo.comTuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 15, 2025 | prnewswire.comTuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect ConferenceMay 13, 2025 | prnewswire.comTuHURA Biosciences (HURA) Projected to Post Earnings on TuesdayMay 8, 2025 | marketbeat.comKineta Amends Merger Agreement with TuHURA BiosciencesMay 7, 2025 | tipranks.com Get TuHURA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HURA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HURA Media Mentions By Week HURA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HURA News Sentiment▼1.881.05▲Average Medical News Sentiment HURA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HURA Articles This Week▼22▲HURA Articles Average Week Get the Latest News and Ratings for HURA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for TuHURA Biosciences and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SNDL News Today ZVRA News Today ARCT News Today SVRA News Today OPT News Today PVLA News Today SEPN News Today ARVN News Today BCYC News Today MBX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HURA) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TuHURA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TuHURA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
